Amelioration of airway and GI disease in G551D-CF ferrets by AAV1 and AAV6

Gene Ther. 2024 Sep;31(9-10):499-510. doi: 10.1038/s41434-024-00469-7. Epub 2024 Jul 28.

Abstract

Gene therapy for CF has concentrated on targeting the lung. Here we took a different approach by injecting into the cephalic vein and spraying into the trachea of G551D, CF ferrets either AAV1 or 6 containing Δ27-264-CFTR, a truncated version of CFTR. Treatment with the potentiator VX-770 was halted for 7 days before instillation to induce a disease phenotype. Indeed, all ferrets were pancreas-insufficient when they entered the study. Four ferrets (three receiving AAV1 and one AAV6) were necropsied 48 days after vector delivery, and four (three receiving AAV6, one AAV1) were euthanized or died prior to the planned necropsy. AAV1 or AAV6 vector genomes, mRNA expression, and CFTR protein were detected in all tracheal and lung samples and in the liver, pancreas, and ileum of the treated ferrets. Surface and basal airway cells, pancreatic and bile ducts, and ileal crypts and villi were successfully transduced. Obstruction of the airways accompanied by pulmonary hemorrhaging, plugged pancreatic and bile ducts as well as mucous plugs in the ileum were noticed in untreated but absent from transduced ferrets necropsied at 48 days. Transduction of G551D ferrets suggests that a combination of systemic and airway application may be the preferred route of delivery for CF.

MeSH terms

  • Animals
  • Cystic Fibrosis Transmembrane Conductance Regulator* / genetics
  • Cystic Fibrosis Transmembrane Conductance Regulator* / metabolism
  • Cystic Fibrosis* / genetics
  • Cystic Fibrosis* / therapy
  • Dependovirus* / genetics
  • Disease Models, Animal
  • Ferrets*
  • Genetic Therapy* / methods
  • Genetic Vectors* / administration & dosage
  • Genetic Vectors* / genetics
  • Lung / metabolism
  • Lung / pathology

Substances

  • Cystic Fibrosis Transmembrane Conductance Regulator